Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with pemetrexed and platinum-based chemotherapy within its marketing authorisation for untreated unresectable advanced malignant pleural mesothelioma.
 
Status In progress
Technology type Medicine
Decision Selected
Process STA Standard
ID number 4044

Provisional Schedule

Committee meeting 12 March 2025
Expected publication 28 May 2025

Project Team

Project lead Celia Mayers

Email enquiries

External Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ

Stakeholders

Companies sponsors Merck Sharpe and Dohme
Others Department of Health and Social Care
  NHS England
Patient carer groups Asbestos Victims Support Groups Forum UK
  Asthma and Lung UK
  Black Health Agency for Equality
  Cancer 52
  Cancer Black Care
  Cancer Equality
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  John MacDougall Mesothelioma Trust
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Mesothelioma UK
  Roy Castle Lung Cancer Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  UK Lung Cancer Coalition
Professional groups Association of Cancer Physicians
  Association of Respiratory Nurse
  British Geriatrics Society
  British Institute of Radiology
  British Oncology Pharmacy Association
  British Psychosocial Oncology Society
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  Lung Cancer and Mesothelioma Clinical Expert Group
  Lung Cancer Nursing UK
  National Heart and Lung Institute
  Primary Care Respiratory Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  Specialists
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Aspire Pharma (pemetrexed)
  Bristol Myers Squibb (ipilimumab, nivolumab)
  Dr. Reddy’s Laboratories (UK) (pemetrexed)
  Eli Lilly (pemetrexed)
  Genus (pemetrexed)
  Hospira (carboplatin, cisplatin)
  Pfizer (pemetrexed)
  Sandoz (cisplatin, pemetrexed)
  Seacross Pharmaceuticals (pemetrexed)
  Sun Pharmaceuticals (pemetrexed)
  Zentiva (pemetrexed)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health - Northern Ireland
  GMB - Britain's General Union
  Health and Safety Executive
  Healthcare Improvement Scotland
  Joint Union Asbestos Committee
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Trades Union Congress
  UK Asbestos Training Association
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Bart's Mesothelioma Research
  Cochrane Lung Cancer Group
  Cochrane UK
  Genomics England
  Institute of Cancer Research
  June Hancock Mesothelioma Research
  Fund
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
24 July 2024 Following a request from the company, the timelines for this appraisal have been revised. The committee meeting will be held on 12 March 2025.
12 June 2024 Invitation to participate
17 January 2024 - 14 February 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4044
17 January 2024 - 14 February 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4044
17 January 2024 In progress. Scoping commencing

For further information on our processes and methods, please see our CHTE processes and methods manual